-- Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.
The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said.
"Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.